Line 196: |
Line 196: |
| 20. Houillier C, et al., (2010). IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560–1566, PMID 20975057. | | 20. Houillier C, et al., (2010). IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560–1566, PMID 20975057. |
| | | |
− | 21. Lugowska, I. et al. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. J. Cancer 9, 998–1005 (2018). PMID: 29581779 | + | 21. Lugowska I, et al., (2018). IDH1/2 mutations predict shorter survival in chondrosarcoma. J Cancer 9:998–1005, PMID 29581779. |
| | | |
− | 22. Figueroa, M. E. et al. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 18, 553–567 (2010). PMID: 21130701 | + | 22. Figueroa ME, et al., (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567, PMID 21130701. |
| | | |
− | 23. Green, C. L. et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118, 409–412 (2011). PMID: 21596855 | + | 23. Green CL, et al., (2011). The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118:409–412, PMID 21596855. |
| | | |
− | 24. Chou, W.-C. et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25, 246–253 (2011). PMID: 21079611 | + | 24. Chou W-C, et al., (2011). The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25:246–253, PMID 21079611. |
| | | |
− | 25. Aref, S. et al. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. Clin. Lymphoma Myeloma Leuk. 15, 550–555 (2015). PMID: 26189213 | + | 25. Aref S, et al., (2015). Prevalence and clinical effect of IDH1 and IDH2 mutations among cytogenetically normal acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk 15:550–555, PMID 26189213. |
| | | |
− | 26. Yamaguchi, S. et al. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur. J. Haematol. 92, 471–477 (2013). PMID: 24443894 | + | 26. Yamaguchi S, et al., (2013). IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur J Haematol 92:471–477, PMID 24443894. |
| | | |
− | 27. Cairns, R. A. et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119, 1901–1903 (2012). PMID: 22215888 | + | 27. Cairns RA, et al., (2012). IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119:1901–1903, PMID 22215888. |
| | | |
− | 28. Wang, C. et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126, 1741–1752 (2015). PMID: 26268241 | + | 28. Wang C, et al., (2015). IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126:1741–1752, PMID 26268241. |
| | | |
− | 29. Soundar, S., Danek, B. L. & Colman, R. F. Identification by Mutagenesis of Arginines in the Substrate Binding Site of the Porcine NADP-dependent Isocitrate Dehydrogenase. J. Biol. Chem. 275, 5606–5612 (2000). PMID: 10681542 | + | 29. Soundar S, et al., (2000). Identification by mutagenesis of arginines in the substrate binding site of the porcine NADP-dependent isocitrate dehydrogenase. J Biol Chem 275:5606–5612, PMID 10681542. |
| | | |
− | 30. Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344 (2010). PMID: 20142433 | + | 30. Gross S, et al., (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344, PMID 20142433. |
| | | |
− | 31. Grassian, A. R. et al. IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism. Cancer Res. 74, 3317–3331 (2014). PMID: 24755473 | + | 31. Grassian AR, et al., (2014). IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res 74:3317–3331, PMID 24755473. |
| | | |
− | 32. Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178–184 (2015). PMID: 25599133 | + | 32. Chan SM, et al., (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21:178–184, PMID 25599133. |
| | | |
− | 33. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012). PMID: 22343901 | + | 33. Lu C, et al., (2012). IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478, PMID 22343901. |
| | | |
− | 34. Xu, W. et al. Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases. Cancer Cell 19, 17–30 (2011). PMID: 26686626 | + | 34. Xu W, et al., (2011). Oncometabolite 2-Hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30, PMID 26686626. |
| | | |
− | 35. Sulkowski, P. L. et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med. 9, eaal2463 (2017). PMID: 28148839 | + | 35. Sulkowski PL, et al., (2017). 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med 9:eaal2463, PMID 28148839. |
| | | |
− | 36. Molenaar, R. J. et al. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clin. Cancer Res. 24, 1705–1715 (2018). PMID: 29339439 | + | 36. Molenaar RJ, et al., (2018). IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clin Cancer Res 24:1705–1715, PMID 29339439. |
| | | |
− | 37. Saha, S. K. et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov. 6, 727–739 (2016). PMID: 27231123 | + | 37. Saha SK, et al., (2016). Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov 6:727–739, PMID 27231123. |
| | | |
− | 38. Li, S. et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncol. 15, 57–68 (2013). PMID: 23115158 | + | 38. Li S, et al., (2013). Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncol 15:57–68, PMID 23115158. |
| | | |
− | 39. Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722–731 (2017). PMID: 28588020 | + | 39. Stein EM, et al., (2017). Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130:722–731, PMID 28588020. |
| | | |
− | 40. Konopleva, M. et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 6, 1106–1117 (2016). PMID: 27520294 | + | 40. Konopleva M, et al., (2016). Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6:1106–1117, PMID 27520294. |
| | | |
− | 41. Tateishi, K. et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell 28, 773–784 (2015). PMID: 26678339 | + | 41. Tateishi K, et al., (2015). Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell 28:773–784, PMID 26678339. |
| | | |
| == Notes == | | == Notes == |